Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy
Introduction. To compare the effect and safety of intravitreal conbercept (IVC), intravitreal ranibizumab (IVR), or intravitreal triamcinolone acetonide (IVTA) injection on 23-gauge (23-G) pars plana vitrectomy (PPV) for proliferative diabetic retinopathy (PDR). Methods. Fifty patients (60 eyes) of...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2018/4927259 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554268585885696 |
|---|---|
| author | Jinglin Cui Hong Chen Hang Lu Fangtian Dong Dongmei Wei Yan Jiao Steve Charles Weikuan Gu Lin Wang |
| author_facet | Jinglin Cui Hong Chen Hang Lu Fangtian Dong Dongmei Wei Yan Jiao Steve Charles Weikuan Gu Lin Wang |
| author_sort | Jinglin Cui |
| collection | DOAJ |
| description | Introduction. To compare the effect and safety of intravitreal conbercept (IVC), intravitreal ranibizumab (IVR), or intravitreal triamcinolone acetonide (IVTA) injection on 23-gauge (23-G) pars plana vitrectomy (PPV) for proliferative diabetic retinopathy (PDR). Methods. Fifty patients (60 eyes) of varying degrees of PDR were randomly grouped into 3 groups (1 : 1 : 1) (n=20 in each group). The 23-G PPV was performed with intravitreal conbercept or ranibizumab injection 3–7 days before surgery or intravitreal TA injection during surgery. The experiment was randomized controlled, with a noninferiority limit of five letters. Main outcome measures included BCVA, operation time, incidence of iatrogenic retinal breaks, endodiathermy rate, and silicone oil tamponade. Results. At 6 months after surgery, there were no significant differences of BCVA improvements, operation time, incidence of iatrogenic retinal breaks, endodiathermy rate, silicone oil tamponade, vitreous clear-up time, and the incidence of intraoperative bleeding between the IVC and IVR groups (all P values ≥ 0.05), but they were significantly different from the IVTA group (all P values < 0.05). IOP increases did not show significant differences between the IVC and IVR groups, but both were significantly different with the IVTA group. More patients had higher postoperative IOP in the IVTA group. Conclusions. The intravitreal injection of conbercept, ranibizumab, or TA for PDR had a significant different effect on outcomes of 23-G PPV surgery. Conbercept and ranibizumab can reduce difficulty of the operation, improve the success rate of PPV surgery, and decrease the incidence of postoperative complications. |
| format | Article |
| id | doaj-art-14df51a984c04611a7ba1172d3a1a79e |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-14df51a984c04611a7ba1172d3a1a79e2025-02-03T05:51:58ZengWileyJournal of Ophthalmology2090-004X2090-00582018-01-01201810.1155/2018/49272594927259Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic RetinopathyJinglin Cui0Hong Chen1Hang Lu2Fangtian Dong3Dongmei Wei4Yan Jiao5Steve Charles6Weikuan Gu7Lin Wang8Center of Integrative Research, The First Hospital of Qiqihar City, Qiqihar, Heilongjiang 161005, ChinaCenter of Integrative Research, The First Hospital of Qiqihar City, Qiqihar, Heilongjiang 161005, ChinaCenter of Integrative Research, The First Hospital of Qiqihar City, Qiqihar, Heilongjiang 161005, ChinaDepartment of Ophthalmology, Peking Union Medical College Hospital, Beijing 100730, ChinaCenter of Integrative Research, The First Hospital of Qiqihar City, Qiqihar, Heilongjiang 161005, ChinaDepartment of Orthopedic Surgery and BME-Campbell Clinic, University of Tennessee Health Science Center, Memphis, TN 38163, USADepartment of Ophthalmology, University of Tennessee Health Science Center, Memphis, TN 38163, USADepartment of Orthopedic Surgery and BME-Campbell Clinic, University of Tennessee Health Science Center, Memphis, TN 38163, USACenter of Integrative Research, The First Hospital of Qiqihar City, Qiqihar, Heilongjiang 161005, ChinaIntroduction. To compare the effect and safety of intravitreal conbercept (IVC), intravitreal ranibizumab (IVR), or intravitreal triamcinolone acetonide (IVTA) injection on 23-gauge (23-G) pars plana vitrectomy (PPV) for proliferative diabetic retinopathy (PDR). Methods. Fifty patients (60 eyes) of varying degrees of PDR were randomly grouped into 3 groups (1 : 1 : 1) (n=20 in each group). The 23-G PPV was performed with intravitreal conbercept or ranibizumab injection 3–7 days before surgery or intravitreal TA injection during surgery. The experiment was randomized controlled, with a noninferiority limit of five letters. Main outcome measures included BCVA, operation time, incidence of iatrogenic retinal breaks, endodiathermy rate, and silicone oil tamponade. Results. At 6 months after surgery, there were no significant differences of BCVA improvements, operation time, incidence of iatrogenic retinal breaks, endodiathermy rate, silicone oil tamponade, vitreous clear-up time, and the incidence of intraoperative bleeding between the IVC and IVR groups (all P values ≥ 0.05), but they were significantly different from the IVTA group (all P values < 0.05). IOP increases did not show significant differences between the IVC and IVR groups, but both were significantly different with the IVTA group. More patients had higher postoperative IOP in the IVTA group. Conclusions. The intravitreal injection of conbercept, ranibizumab, or TA for PDR had a significant different effect on outcomes of 23-G PPV surgery. Conbercept and ranibizumab can reduce difficulty of the operation, improve the success rate of PPV surgery, and decrease the incidence of postoperative complications.http://dx.doi.org/10.1155/2018/4927259 |
| spellingShingle | Jinglin Cui Hong Chen Hang Lu Fangtian Dong Dongmei Wei Yan Jiao Steve Charles Weikuan Gu Lin Wang Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy Journal of Ophthalmology |
| title | Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy |
| title_full | Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy |
| title_fullStr | Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy |
| title_full_unstemmed | Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy |
| title_short | Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy |
| title_sort | efficacy and safety of intravitreal conbercept ranibizumab and triamcinolone on 23 gauge vitrectomy for patients with proliferative diabetic retinopathy |
| url | http://dx.doi.org/10.1155/2018/4927259 |
| work_keys_str_mv | AT jinglincui efficacyandsafetyofintravitrealconberceptranibizumabandtriamcinoloneon23gaugevitrectomyforpatientswithproliferativediabeticretinopathy AT hongchen efficacyandsafetyofintravitrealconberceptranibizumabandtriamcinoloneon23gaugevitrectomyforpatientswithproliferativediabeticretinopathy AT hanglu efficacyandsafetyofintravitrealconberceptranibizumabandtriamcinoloneon23gaugevitrectomyforpatientswithproliferativediabeticretinopathy AT fangtiandong efficacyandsafetyofintravitrealconberceptranibizumabandtriamcinoloneon23gaugevitrectomyforpatientswithproliferativediabeticretinopathy AT dongmeiwei efficacyandsafetyofintravitrealconberceptranibizumabandtriamcinoloneon23gaugevitrectomyforpatientswithproliferativediabeticretinopathy AT yanjiao efficacyandsafetyofintravitrealconberceptranibizumabandtriamcinoloneon23gaugevitrectomyforpatientswithproliferativediabeticretinopathy AT stevecharles efficacyandsafetyofintravitrealconberceptranibizumabandtriamcinoloneon23gaugevitrectomyforpatientswithproliferativediabeticretinopathy AT weikuangu efficacyandsafetyofintravitrealconberceptranibizumabandtriamcinoloneon23gaugevitrectomyforpatientswithproliferativediabeticretinopathy AT linwang efficacyandsafetyofintravitrealconberceptranibizumabandtriamcinoloneon23gaugevitrectomyforpatientswithproliferativediabeticretinopathy |